VEA
CNST

Virtus ETF Advisers’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Virtus ETF Advisers’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,500
Closed -$222K – 408
2021
Q1 		$222K Buy
9,500
+169
+2% +$5.12K 0.09% 312
2020
Q4 		$269K Buy
9,331
+391
+4% +$9.84K 0.11% 284
2020
Q3 		$181K Sell
8,940
-1,217
-12% -$29.7K 0.09% 308
2020
Q2 		$305K Buy
10,157
+1,035
+11% +$37.3K 0.14% 301
2020
Q1 		$287K Sell
9,122
-1,343
-13% -$46.7K 0.12% 229
2019
Q4 		$493K Buy
+10,465
New +$302K 0.08% 205

Other funds holding CNST

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtus ETF Advisers's CNST Position: Q2 2021 in Review

Virtus ETF Advisers sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q2 2021, closing a stake of 9,500 shares — an estimated $222K sold.

Virtus ETF Advisers first reported a position in CNST in Q4 2019 and held it in 6 quarters. The position peaked at $493K in Q4 2019. 153 funds tracked by Wall St. Rank hold CNST as of Q2 2021.

  • Virtus ETF Advisers reported no remaining Constellation Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 9,500 Constellation Pharmaceuticals, Inc. shares in Q2 2021, an estimated $222K.
  • Virtus ETF Advisers first reported a position in Constellation Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
  • Virtus ETF Advisers's Constellation Pharmaceuticals, Inc. position peaked at $493K in Q4 2019.
  • 153 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q2 2021.

Based on Virtus ETF Advisers's 13F filing for Q2 2021, filed 10 Aug 2021.